The company is also expecting a decision in second-half 2013 for its antipsychotic cariprazine (a new, second-generation drug targeting dopamine D3 receptors) being developed for the treatment of both schizophrenia and bipolar mania. Analytics outfit Datamonitor cogently noted in a research report, however, that although Forest's experience in the psychiatry market will be a distinct commercial advantage, the firm will still need to demonstrate clinical benefits associated with the drug’s novel mechanism of action.
Source: http://ycharts.com/analysis/story/is_there_a_pill_for_that_forest_labs_iffy_pipeline
Source: http://ycharts.com/analysis/story/is_there_a_pill_for_that_forest_labs_iffy_pipeline